PLRX Stock Overview
A clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pliant Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.84 |
| 52 Week High | US$19.62 |
| 52 Week Low | US$10.29 |
| Beta | 1.15 |
| 11 Month Change | -0.75% |
| 3 Month Change | 0.34% |
| 1 Year Change | -26.05% |
| 33 Year Change | -35.09% |
| 5 Year Change | n/a |
| Change since IPO | -44.41% |
Recent News & Updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings
Jan 21
Shareholder Returns
| PLRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.0% | 0.6% | 1.6% |
| 1Y | -26.0% | 16.9% | 22.0% |
Return vs Industry: PLRX underperformed the US Pharmaceuticals industry which returned 16.3% over the past year.
Return vs Market: PLRX underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| PLRX volatility | |
|---|---|
| PLRX Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PLRX has not had significant price volatility in the past 3 months.
Volatility Over Time: PLRX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 166 | Bernard Coulie | pliantrx.com |
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.
Pliant Therapeutics, Inc. Fundamentals Summary
| PLRX fundamental statistics | |
|---|---|
| Market cap | US$719.89m |
| Earnings (TTM) | -US$185.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs PLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$185.41m |
| Earnings | -US$185.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.7% |
How did PLRX perform over the long term?
See historical performance and comparison